Jennifer Jarrett - Dec 20, 2021 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Chief Operating Officer, Director
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Stock symbol
RCUS
Transactions as of
Dec 20, 2021
Transactions value $
-$1,444,369
Form type
4
Date filed
12/22/2021, 04:03 PM
Previous filing
Dec 20, 2021
Next filing
Feb 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Sale -$454K -11.1K -8.85% $40.88 114K Dec 20, 2021 Direct F1, F2
transaction RCUS Common Stock Sale -$872K -20.9K -18.3% $41.70 93.4K Dec 20, 2021 Direct F1, F3
transaction RCUS Common Stock Sale -$118K -2.8K -3% $42.23 90.6K Dec 20, 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.16 to $41.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.16 to $42.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.16 to $42.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.